Neonatal Seizures and Purinergic Signalling

Area of Science:

• Neuroscience
• Developmental Biology
• Pharmacology

Background:

• Neonatal seizures are a common complication of neonatal encephalopathy, often exacerbating brain injury and impacting outcomes.
• Existing anti-seizure medications face challenges with pharmacoresistance and potential neurotoxicity in infants.
• The purinergic system, involving adenosine triphosphate and purinoreceptors, is a key signaling pathway in the central nervous system.

Purpose of the Study:

• To review the pathology of neonatal seizures and the role of purinergic signaling during brain development.
• To examine emerging evidence linking purinergic signaling to neonatal seizures.
• To discuss potential purine-based therapeutic strategies for neonatal seizure suppression.

Main Methods:

• Literature review of neonatal seizure pathology.
• Analysis of purinergic signaling mechanisms in the developing brain.
• Synthesis of recent research on purinergic system involvement in neonatal seizures.

Main Results:

• Purinergic signaling components are widely expressed during brain development.
• Evidence suggests purinergic signaling plays a role in the pathophysiology of neonatal seizures.
• Targeting the purinergic system has shown potential for both convulsive and anticonvulsive effects.

Conclusions:

• The purinergic system represents a promising therapeutic target for neonatal seizures.
• Developing novel purine-based treatments could offer safer alternatives to current anti-seizure medications.
• Further research into purinergic signaling pathways is crucial for advancing neonatal seizure management.